ZIOPHARM Oncology Inc Total Assets 2006-2021 | ZIOP

ZIOPHARM Oncology Inc total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
ZIOPHARM Oncology Inc Annual Total Assets
(Millions of US $)
2020 $146
2019 $109
2018 $95
2017 $106
2016 $106
2015 $154
2014 $45
2013 $72
2012 $83
2011 $108
2010 $62
2009 $50
2008 $13
2007 $37
2006 $30
2005 $9
ZIOPHARM Oncology Inc Quarterly Total Assets
(Millions of US $)
2021-09-30 $114
2021-06-30 $107
2021-03-31 $128
2020-12-31 $146
2020-09-30 $166
2020-06-30 $182
2020-03-31 $198
2019-12-31 $109
2019-09-30 $118
2019-06-30 $73
2019-03-31 $84
2018-12-31 $95
2018-09-30 $67
2018-06-30 $76
2018-03-31 $87
2017-12-31 $106
2017-09-30 $117
2017-06-30 $127
2017-03-31 $94
2016-12-31 $106
2016-09-30 $117
2016-06-30 $128
2016-03-31 $142
2015-12-31 $154
2015-09-30 $173
2015-06-30 $124
2015-03-31 $132
2014-12-31 $45
2014-09-30 $49
2014-06-30 $55
2014-03-31 $63
2013-12-31 $72
2013-09-30 $29
2013-06-30 $46
2013-03-31 $63
2012-12-31 $83
2012-09-30 $106
2012-06-30 $122
2012-03-31 $141
2011-12-31 $108
2011-09-30 $122
2011-06-30 $133
2011-03-31 $131
2010-12-31 $62
2010-09-30 $67
2010-06-30 $74
2010-03-31 $46
2009-12-31 $50
2009-09-30 $8
2009-06-30 $5
2009-03-31 $8
2008-12-31 $13
2008-09-30 $17
2008-06-30 $22
2008-03-31 $29
2007-12-31 $37
2007-09-30 $43
2007-06-30 $49
2007-03-31 $54
2006-12-31 $30
2006-09-30 $35
2006-06-30 $38
2006-03-31 $6
2005-12-31 $9
2005-09-30 $11
2005-06-30 $0
2005-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.264B $0.000B
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90